Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Phathom Pharmaceuticals to post earnings of ($0.09) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Down 6.9%

Shares of NASDAQ PHAT opened at $11.88 on Thursday. The firm has a market cap of $848.47 million, a price-to-earnings ratio of -3.11 and a beta of 0.51. The company’s 50-day simple moving average is $14.77 and its 200-day simple moving average is $13.36. Phathom Pharmaceuticals has a 52-week low of $2.21 and a 52-week high of $18.31.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on PHAT shares. Barclays initiated coverage on Phathom Pharmaceuticals in a report on Monday, December 8th. They issued an “equal weight” rating and a $16.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price target on shares of Phathom Pharmaceuticals in a research note on Thursday, October 30th. HC Wainwright increased their price objective on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Raymond James Financial initiated coverage on Phathom Pharmaceuticals in a report on Thursday, December 11th. They issued a “strong-buy” rating and a $28.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.71.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Phathom Pharmaceuticals by 0.8% in the second quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock valued at $1,328,000 after purchasing an additional 1,123 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Phathom Pharmaceuticals by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,826 shares of the company’s stock valued at $152,000 after purchasing an additional 1,364 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Phathom Pharmaceuticals in the 4th quarter valued at approximately $27,000. AQR Capital Management LLC increased its holdings in shares of Phathom Pharmaceuticals by 3.5% during the 4th quarter. AQR Capital Management LLC now owns 54,448 shares of the company’s stock worth $903,000 after buying an additional 1,819 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Phathom Pharmaceuticals by 58.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock valued at $55,000 after buying an additional 2,102 shares during the period. Institutional investors and hedge funds own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.